Brief: Mabpharm Posts FY Loss Attributable Of RMB209.4 Mln
26/03/2024 15:14
March 26 (Reuters) - Mabpharm Ltd 2181.HK :
* FY LOSS ATTRIBUTABLE RMB209.4 MILLION VERSUS RMB210.8
MILLION
LOSS
* FY REVENUE RMB87.2 MILLION, UP 55.9%
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008